{"nctId":"NCT00690612","briefTitle":"Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)","startDateStruct":{"date":"2007-09"},"conditions":["Hypertension"],"count":35,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: candesartan cilexetil"]}],"interventions":[{"name":"candesartan cilexetil","otherNames":["Atacand"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must have participated in Protocol 328 (without discontinuation due to a study drug related AE).\n* Must sign an informed consent prior to initiating any stus dy procedures.\n* Have, in the opinion of the investigator, an on-going clinical indication for oral liquid formulation of candesartan cilexetil to control hypertension\n* Weight ≥ 10 kg and ≤ 40 kg.\n\nExclusion Criteria:\n\n* Any situation, clinical condition (such as clinically significant declining renal function) or laboratory abnormality that, in the opinion of the investigator or sponsor, may interfere with the subject's participation in the study.\n* Estimated glomerular filtration rate (GFR) \\<30 ml/min/1.73m2 for non-transplant patients and \\<40 ml/min/1.73m2 for transplant patients based on the Schwartz Formula (Schwartz et al 1987) as determined at enrollment into Study 328.\n* Impaired liver function defined as either acute liver disease or chronic liver disease with persistently elevated liver enzyme values judged clinically significant by the investigator.\n* Currently using any medications that, in the opinion of the investigator could negatively affect the subject when given together with candesartan cilexetil.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"10 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline to Final Visit in Systolic Blood Pressure (SBP).","description":"Blood pressure response was defined as Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) less than the 95th percentile based on population height-adjusted charts for age and gender. Response rates were based on the proportion of patients meeting the criteria at each evaluation time point or the last available measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.86","spread":"11.97"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Final Visit in Diastolic Blood Pressure (DBP).","description":"Blood pressure response was defined as Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) less than the 95th percentile based on population height-adjusted charts for age and gender. Response rates were based on the proportion of patients meeting the criteria at each evaluation time point or the last available measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"12.26"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":35},"commonTop":["PYREXIA","Diarrhoea","PHARYNGITIS","RHINITIS","COUGH"]}}}